Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose
- 12 April 2005
- journal article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 5 (3) , 193-202
- https://doi.org/10.1038/sj.tpj.6500308
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- The Pharmacology and Management of the Vitamin K AntagonistsChest, 2004
- Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarinClinical Pharmacology & Therapeutics, 2004
- Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarinThe Pharmacogenomics Journal, 2003
- Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearanceClinical Pharmacology & Therapeutics, 2002
- The Frequency and Effects of Cytochrome P450 (CYP) 2C9 Polymorphisms in Patients Receiving WarfarinJournal of the American College of Surgeons, 2002
- Cytochrome P450 polymorphisms are associated with reduced warfarin doseSurgery, 2000
- CYP2C9*3 allelic variant and bleeding complicationsThe Lancet, 1999
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- Human P450 metabolism of warfarinPharmacology & Therapeutics, 1997
- Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac‐warfarin [see comments]British Journal of Clinical Pharmacology, 1994